Indaptus Therapeutics Q3 profit beats estimates

Indaptus Therapeutics

12/11/2025 13:38

Overview

Indaptus Q3 2025 EPS beats analyst expectations, improving from last year's loss

Company raised $2.3 mln through at-the-market facility, strengthening balance sheet

Research and development expenses increased due to Phase 1 study costs

Outlook

Indaptus expects current cash to support operations into Q1 2026

Company is evaluating financing options to support its strategy

Indaptus pauses trial enrollment pending further efficacy evaluations

Result Drivers

BALANCE SHEET STRENGTHENED - Raised $2.3 mln through at-the-market facility

R&D EXPENSES - Increase due to Phase 1 study costs

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 EPS
Beat
-$2.98
-$4.17 (1 Analyst)

Analyst Coverage

The one available analyst rating on the shares is "buy"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Indaptus Therapeutics Inc is $25.00, about 89.1% above its November 11 closing price of $2.72

Press Release: ID:nGNXxXz2j

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)